6MX.F - Eidos Therapeutics, Inc.
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Show:
Annual
Income Statement
All numbers in thousandsBreakdown
ttm
2018-12-31
2017-12-31
2016-12-31
Total Revenue
26,691
0
0
0
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
41,356
28,539
9,286
1,734
Selling General and Administrative
14,667
9,240
2,730
651
Total Operating Expenses
56,023
37,779
12,016
2,385
Operating Income or Loss
-31,832
-37,779
-12,016
-2,385
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-4,313
-2,946
75
-157
Income Before Tax
-36,145
-40,725
-11,941
-2,542
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-36,145
-40,725
-11,941
-2,542
Net Income
-36,145
-40,725
-11,941
-2,542
Net Income available to common shareholders
-29,622
-40,725
-11,941
-2,542
Reported EPS
Basic
-
-1.86
-0.93
-0.13
Diluted
-
-1.86
-0.93
-0.13
Weighted average shares outstanding
Basic
-
21,367
12,777
19,575
Diluted
-
21,367
12,777
19,575
EBITDA
-
-37,779
-12,012
-2,385